Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275972 · ClinicalTrials.gov registry record · Phase 3
Descemet Endothelial Thickness Comparison Trial II
A Phase 3 study of Fuchs Endothelial Dystrophy and Fuchs, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 7
- Study locations
NCT05275972: Recruiting Phase 3 study of Fuchs Endothelial Dystrophy and Fuchs, sponsored by Stanford University.
NCT05275972 is a Phase 3 study of Fuchs Endothelial Dystrophy and Fuchs that is actively recruiting participants, run by Stanford University. The registered enrollment target is 60 participants, below the 489-participant average among 7 other Fuchs Endothelial Dystrophy trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275972, a Phase 3 study of Fuchs Endothelial Dystrophy and Fuchs, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 7
- Study locations
Study Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Primary Outcome
Best spectacle-corrected visual acuity (BSCVA)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ripasudil
Study Locations (7)
California
- Stanford University - Palo Alto
- University of California Davis - Sacramento
Pennsylvania
- University of Pennsylvania - Philadelphia
- Wills Eye Hospital - Philadelphia
Florida
- University of Miami - Palm Beach Gardens
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 3 |
What NCT05275972 shows while recruiting
NCT05275972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 489-participant average among 7 other Fuchs Endothelial Dystrophy trials with a reported enrollment target (88% lower).
The record links to 3 conditions, with Fuchs Endothelial Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05275972 lists 7 locations in 5 states (California, Pennsylvania, Florida).
Frequently Asked Questions
What is clinical trial NCT05275972 about?
NCT05275972 is a clinical study titled "Descemet Endothelial Thickness Comparison Trial II". Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
What is the current status of trial NCT05275972?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2023-01-23. Estimated completion is 2028-11-30.
What conditions does trial NCT05275972 study?
This clinical trial studies the following conditions: Fuchs Endothelial Dystrophy, Fuchs, Fuchs Dystrophy.
What interventions are being tested in trial NCT05275972?
The interventions under investigation include: Placebo (DRUG), Ripasudil (DRUG).
Who is sponsoring clinical trial NCT05275972?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275972 being conducted?
This trial has 7 study locations across California, Florida, New Hampshire, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fuchs Endothelial Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
RECRUITING · Phase 2
-
DISCOVER Study: Microscope-integrated Intraoperative OCT Study
RECRUITING
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy
RECRUITING · Phase 4
-
Plasma Rich in Growth Factors in Corneal Endothelial Transplantation
RECRUITING · NA
-
Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI